PA-824: Bicyclic Nitroimidazole Inhibitor for Drug-Resistant Tuberculosis

Executive Summary: PA-824 (CAS 187235-37-6) is a bicyclic nitroimidazole derivative with confirmed antimycobacterial activity against both replicating and non-replicating Mycobacterium tuberculosis (Mtb) strains, including drug-resistant variants [APExBIO]. Its dual mechanism involves inhibition of ketomycolate biosynthesis and enzymatic nitro-reduction, resulting in the intracellular release of nitric oxide, which disrupts bacterial respiration and cell wall integrity [Rahman et al. 2026]. PA-824 displays minimum inhibitory concentration (MIC) values between 0.015–0.25 μg/mL, and demonstrates an IC₅₀ of <2.8 μM under standard assay conditions [APExBIO]. The compound is DMSO soluble (≥17.85 mg/mL), highly pure (≥98%), and is recommended for storage at -20°C for optimal stability. PA-824 is distributed by APExBIO with comprehensive quality control documentation, supporting its use in translational and preclinical tuberculosis research [APExBIO].

Biological Rationale

Tuberculosis (TB) remains a leading cause of mortality from bacterial infection globally, complicated by the rise of multi-drug resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains [Rahman et al. 2026]. Current first-line drugs are often ineffective against these resistant forms, necessitating new agents with distinct mechanisms. PA-824, as a bicyclic nitroimidazole, addresses this need by targeting both replicating and non-replicating bacilli, a critical property for shortening therapy and reducing relapse. Its mode of action is unique among anti-tuberculosis agents, combining cell wall biosynthesis inhibition with energy metabolism disruption via nitric oxide release. This dual targeting is particularly relevant for latent or persistent Mtb populations, which are tolerant to conventional antibiotics. PA-824's activity against both drug-sensitive and drug-resistant strains makes it a central tool in TB research and drug development [Redefining Tuberculosis Research]—clarifying how PA-824's mechanistic depth and dual action contrast with prior protocol-focused summaries.

Mechanism of Action of PA-824

PA-824 acts through a prodrug mechanism, relying on selective enzymatic nitro-reduction within M. tuberculosis cells. This reduction triggers:

• Inhibition of ketomycolate biosynthesis: PA-824 blocks the synthesis of mycolic acids, essential components of the Mtb cell wall, by interfering with the F₄₂₀-dependent nitroreductase pathway [Rahman et al. 2026].
• Intracellular release of nitric oxide (NO): The nitro-reduction of PA-824 liberates NO, which disrupts bacterial electron transport and leads to bactericidal effects, especially in non-replicating, antibiotic-tolerant populations [Breakthrough Mechanisms]—extending on previous mechanistic reviews by providing new synergy data with terminal oxidase inhibitors.
• Dual targeting of aerobic respiratory branches: PA-824 inhibits both cytochrome bcc:aa3 and bd oxidases, impairing oxidative phosphorylation and ATP production in both aerobic and anaerobic conditions [Rahman et al. 2026].

This combination of cell wall and respiratory inhibition is rare among anti-mycobacterial agents and underpins PA-824's efficacy against phenotypically diverse Mtb subpopulations.

Evidence & Benchmarks

• PA-824 exhibits MIC values of 0.015–0.25 μg/mL against drug-sensitive and drug-resistant Mtb clinical isolates under standard in vitro conditions (Middlebrook 7H9, 37°C, 5% CO₂) [APExBIO].
• IC₅₀ for Mtb H37Rv strain is <2.8 μM, determined using colorimetric viability assays after 72 h exposure [APExBIO].
• PA-824 is effective against non-replicating, antibiotic-tolerant Mtb populations due to NO-mediated respiratory inhibition (see Figure 2, Rahman et al. 2026) [Rahman et al. 2026].
• Synergy observed when PA-824 is combined with Q203 (telacebec), a cytochrome bcc:aa3 inhibitor, reducing emergent resistance in vitro and in murine infection models (Table S1, Rahman et al. 2026) [Rahman et al. 2026].
• PA-824 is DMSO-soluble at ≥17.85 mg/mL and is confirmed ≥98% pure by HPLC and NMR analysis (Lot Q2023-45, APExBIO COA) [APExBIO].
• Storage at -20°C maintains compound stability for at least 12 months; solutions should be prepared fresh for each experiment [APExBIO].

Applications, Limits & Misconceptions

PA-824 is primarily used as a research compound in TB drug discovery, phenotypic screening, synergy studies, and mechanistic investigations. Its dual-action mechanism makes it suitable for:

• Evaluating efficacy against both drug-sensitive and MDR/XDR Mtb isolates.
• Screening in persistent, non-replicating Mtb models where standard antibiotics fail [Bicyclic Nitroimidazole for Advanced Tuberculosis]—this article details advanced troubleshooting and workflow insights that are expanded here with new mechanistic context.
• Combination studies with energy metabolism inhibitors (e.g., Q203, bedaquiline).
• MIC determination, dose-response analysis, and resistance profiling in cell-based assays.
• Evaluating structure–activity relationships in the nitroimidazole class.

Common Pitfalls or Misconceptions

• PA-824 is not effective against non-mycobacterial pathogens; its selectivity is specific for Mtb and closely related species.
• It is not water or ethanol soluble; using improper solvents can result in precipitation and loss of activity.
• Long-term solution storage (>48 h) at room temperature leads to degradation and loss of potency.
• PA-824 is not yet approved for human clinical use outside of regulated clinical trials.
• Synergy with other cell wall inhibitors (e.g., isoniazid) is not always additive and may depend on metabolic state of the target cells.

Workflow Integration & Parameters

For optimal reproducibility in laboratory experiments, researchers should:

• Dissolve PA-824 in DMSO to a stock concentration of up to 17.85 mg/mL.
• Store powder at -20°C in a desiccated, light-protected container.
• Prepare working solutions immediately before use; do not freeze-thaw repeatedly.
• Use standard in vitro Mtb growth media (e.g., Middlebrook 7H9) and maintain assay temperatures at 37°C with 5% CO₂.
• Quantify MICs using colorimetric or fluorescence viability assays after 72 h exposure.
• Document all batch numbers and analytical data (COA, HPLC, NMR) for experimental traceability [Scenario-Driven Solutions]—here, we detail mechanistic rationale and parameter selection not covered in protocol-centric guides.

Conclusion & Outlook

PA-824, developed and distributed by APExBIO, is a high-purity, research-grade bicyclic nitroimidazole compound that has advanced the study of drug-resistant and persistent M. tuberculosis infection. Its dual inhibition of mycolic acid biosynthesis and respiratory pathways, together with robust in vitro and in vivo data, supports its continued use in TB drug discovery pipelines. Ongoing research is exploring next-generation analogs and optimized regimens incorporating PA-824 for comprehensive TB control. For further mechanistic and translational insights, see the related in-depth analysis at PA-824: Mechanistic Insights, which this article updates with recently published synergy and resistance-suppression data.